ArticleJHEP reports : innovation in hepatology2026
HBV X protein regulates cancer stemness and tumor invasiveness through SENP1 in hepatocellular carcinoma.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: The niche in hepatocellular carcinoma (HCC) critically influences cancer stem cell (CSC)-associated properties, including stemness, early recurrence, and poor prognoses. HBV infection acts as a niche driver for tumor progression and malignancy. While the HBV X (HBx) protein has been linked to CSC-associated properties, the underlying molecular mechanisms remain unclear. Methods: Paired tumor and peritumor tissues from 211 patients with HCC were analyzed to correlate Results: Clinically, SENP1 expression was correlated with OCT4, SNAIL, and TWIST ( Conclusions: HBx-induced SENP1 is critical for CSC properties. SENP1 can serve as a novel biomarker for early recurrence, metastasis, and drug resistance, particularly in HBV-related HCC. Impact and implications: Early recurrence, tumor metastasis, and drug resistance are significant therapeutic challenges in hepatocellular carcinoma (HCC), which are closely associated with cancer stem cell (CSC)-related properties. In this study, we demonstrated that HBx-induced SENP1 expression regulates CSC-related properties and tumor metastasis, particularly in HBV-related HCC, in clinical,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.